NDTV Profit on MSN
Citi picks Divi's as top India pharma bet, sees peptide pipeline driving next leg of growth
The brokerage expects supplies for GLP-1 molecules to begin in FY27, while two key oral peptide opportunities, Enlicitide and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results